Deven V Parmar
Zydus Therapeutics Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Deven V Parmar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:41 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07023835 · Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral SclerosisZydus Therapeutics Inc. · recruiting · Amyotrophic Lateral Sclerosis (ALS) · study director
- Ph2NCT05211284 · Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USZydus Therapeutics Inc. · terminated · Nonalcoholic Fatty Liver Disease · study director
- Ph2/Ph3NCT05133336 · Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisZydus Therapeutics Inc. · completed · Primary Biliary Cholangitis · study director
- Ph1NCT05045482 · Hepatic Impairment With Cirrhosis Due to Cholestatic Liver DiseaseZydus Therapeutics Inc. · recruiting · Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease · study director
- Ph2NCT05011305 · Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisZydus Therapeutics Inc. · completed · Nonalcoholic Steatohepatitis, Fibrosis · study director
- Ph1NCT04045769 · A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy VolunteersZydus Therapeutics Inc. · completed · Healthy · study director
- Ph2NCT03863574 · Saroglitazar Magnesium in the Treatment of Non-Alcoholic SteatohepatitisZydus Therapeutics Inc. · completed · Non Alcoholic Steatohepatitis · study director
- Ph2NCT03097107 · Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dLZydus Therapeutics Inc. · suspended · Dyslipidemias · study director
- Ph2NCT03061721 · Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic SteatohepatitisZydus Therapeutics Inc. · completed · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:41 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:41 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis.J Hepatol · 202272 citationsRCR 5.8
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).Clin Pharmacol Drug Dev · 202370 citationsRCR 6.6
- Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.Am J Nephrol · 201966 citationsRCR 3.2
- Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.Acta Diabetol · 202018 citationsRCR 0.9
- High-performance thin-layer chromatographic determination of flurbiprofen in plasma.J Chromatogr B Biomed Sci Appl · 199714 citationsRCR 0.8
- Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.Clin Drug Investig · 201811 citationsRCR 0.5
- 3 citationsRCR 0.2
- Comparative pharmacodynamic-pharmacokinetic correlation of oral sustained-release theophylline formulation in adult asthmatics.Drug Dev Ind Pharm · 19991 citationsRCR 0.0
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants.Naunyn Schmiedebergs Arch Pharmacol · 20241 citationsRCR 0.3
- 0 citationsRCR 0.0